Vistin Pharma ASA: Third quarter and YTD 2025 financial results
Oslo, Norway, 31st of October 2025
Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025.
Revenue in the third quarter ended at MNOK 109 compared to MNOK 106 in Q3 2024. The increase in revenue was driven by 10% higher sales volume. Revenue YTD 2025 ended at MNOK 342 compared to MNOK 316 YTD last year, an increase of 8%
Third quarter EBITDA ended at MNOK 28 compared to MNOK 29 in Q3 2024. EBITDA of MNOK 28 positively affected by higher sales volume, offset by lower global metformin prices compared to same quarter last year. EBITDA for first three months of 2025 ended at MNOK 89 compared to MNOK 77 YTD 2024, an increase of 16%.
The net profit ended at MNOK 18.5 (16.6) for the third quarter of 2025.
All time high production volume in the quarter with 1 600MT Metformin produced.
The third quarter conference call, which will be held today, 31st of October at 8.30am (CET), will be available via webcast and audio through the following access points:
Webcast:
https://edge.media-server.com/mmc/p/zojifvb6
Telephone conference (online registration):
https://register-conf.media-server.com/register/BI4b6411bcd117427f8df81e59f7b2fd65
The conference call will be held in English.
Please find the Q3 report and presentation enclosed. The report and webcast (recorded) will also be made available on www.vistin.com.
*****
For further information, please contact:
Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
